Evidence map›Paper›PMID 32696118›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2020

Characterizing patients initiating abaloparatide, teriparatide, or denosumab in a real-world setting: a US linked claims and EMR database analysis.

E A Imel, K Starzyk, R Gliklich, R J Weiss, Y Wang, S A Williams

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

E A ImelDepartment of Medicine, Endocrinology, Indiana University School of Medicine, Gatch Hall, Suite 380 F, 1120 W. Michigan St., Indianapolis, IN, 46202-5111, USA. eimel@iu.edu.ORCID https://orcid.org/0000-0002-7284-3467
K StarzykOM1, Inc., 800 Boylston St, Boston, MA, 02199, USA.ORCID https://orcid.org/0000-0001-7171-3989
R GliklichOM1, Inc., 800 Boylston St, Boston, MA, 02199, USA.ORCID https://orcid.org/0000-0001-7552-4640
R J WeissRadius Health, Inc., 950 Winter St, Waltham, MA, 02451, USA.ORCID https://orcid.org/0000-0002-0095-2410
Y WangRadius Health, Inc., 950 Winter St, Waltham, MA, 02451, USA.ORCID https://orcid.org/0000-0002-5741-9836
S A WilliamsRadius Health, Inc., 950 Winter St, Waltham, MA, 02451, USA.ORCID https://orcid.org/0000-0002-6795-2677
Radius Health (United States) · USOffice of Multidisciplinary Activities · USIndiana University School of Medicine

Funding

Radius Health, Inc N/A
6 · The paper itself

Abstract

We characterized patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) in a real-world clinical setting from a large medical and pharmacy claims database. Differences were noted in sex, age, pathologic fractures, comorbidity index, and prior bisphosphonate use for patients initiating ABL and TPTD compared with those receiving DMAB.

introductionTo characterize patients initiating abaloparatide (ABL), teriparatide (TPTD), or denosumab (DMAB) treatment in a real-world clinical setting.

methodsPatients aged ≥ 18 years initiating ABL, TPTD, or DMAB between May 1, 2017, and September 24, 2018 (without receiving the same drug in the previous 12 months), were identified using the OM1 Data Cloud, which contains medical and pharmacy claims from approximately 200 million US patients. The index date was the date of initial prescription or dispensing for ABL, TPTD, or DMAB during the study period.

resultsDuring the study period, 2666 patients initiated ABL, 9210 TPTD, and 116,718 DMAB. Mean age (standard deviation) was 69.2 (10.6) years for the ABL cohort, 68.6 (11.3) for TPTD, and 72.1 (10.2) for DMAB (P < 0.001; ABL vs DMAB). Proportionally more patients initiating ABL were female (95.2% ABL, 86.9% TPTD, and 91.3% DMAB, P < 0.001 ABL vs TPTD or DMAB). Nearly twice as many patients initiating ABL (19.1%) and TPTD (18.8%) had a previous pathologic/fragility fracture vs DMAB (9.6%; P < 0.001 ABL vs DMAB). Fewer patients initiating ABL (36.3%) or TPTD (39.7%) had Charlson comorbidity index of ≥ 2 vs DMAB (48.4%; P < 0.001 ABL vs DMAB). Before initiating ABL, TPTD, or DMAB, 44.3%, 33.8%, and 33.9% of patients had prior osteoporosis treatment, respectively. Bisphosphonate use was more common before initiating ABL (19.2%) or TPTD (19.6%), than before initiating DMAB (16.6%; P < 0.001 ABL vs DMAB).

conclusionsPatients initiating ABL and TPTD differed in sex, age, pathologic fractures, comorbidity index, and prior bisphosphonate use compared with those initiating DMAB.

Indexed as

Bone Density Conservation AgentsOsteoporosis, PostmenopausalAgedBone DensityDenosumabFemaleHumansInfantMaleMedicareParathyroid Hormone-Related ProteinTeriparatideUnited StatesabaloparatideBone Density Conservation AgentsDenosumabParathyroid Hormone-Related ProteinTeriparatideAbaloparatideDenosumabOsteoporosisPatient characteristicsReal-worldTeriparatide

Identifiers

PMID32696118
PMCPMC7661401
OpenAlexW3045416560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.